Idioma:

Nutritional status in patients with phenylketonuria using glycomacropeptide as their major protein source

Pinto, A ; Almeida, M F ; Ramos, P C ; Rocha, S ; Guimas, A ; Ribeiro, R ; Martins, E ; Bandeira, A ; MacDonald, A ; Rocha, J C

European journal of clinical nutrition, 2017-10, Vol.71 (10), p.1230-1234 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Nutritional status in patients with phenylketonuria using glycomacropeptide as their major protein source
Autor: Pinto, A ; Almeida, M F ; Ramos, P C ; Rocha, S ; Guimas, A ; Ribeiro, R ; Martins, E ; Bandeira, A ; MacDonald, A ; Rocha, J C
Assuntos: Adolescent ; Adult ; Amino acids ; Anthropometry ; Biochemical markers ; Blood ; Blood pressure ; Body Composition ; Body composition (biology) ; Carbohydrates ; Caseins - administration & dosage ; Correlation analysis ; Diet ; Dietary Proteins - administration & dosage ; Dietary supplements ; Female ; Glycomacropeptide ; Health aspects ; Hemoglobin ; Humans ; Lipid metabolism ; Lipids ; Longitudinal Studies ; Male ; Markers ; Metabolic disorders ; Metabolism ; Middle Aged ; Nutrition ; Nutritional Status ; Patients ; Peptide Fragments - administration & dosage ; Peptides ; Phenylalanine ; Phenylketonuria ; Phenylketonurias - diet therapy ; Physiological aspects ; Polypeptides ; Portugal ; Protein turnover ; Proteins ; Retrospective Studies ; Statistical analysis ; Substitutes ; Tyrosine ; Young Adult
É parte de: European journal of clinical nutrition, 2017-10, Vol.71 (10), p.1230-1234
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Low phenylalanine (PHE), glycomacropeptide-based protein substitute (GMP) is an alternative to traditional L-amino acid supplements (AA) used in the dietary management of phenylketonuria (PKU). In a retrospective, longitudinal study, we report the nutritional status of PKU patients taking AA and GMP. Eleven PKU patients aged 27±10 years (1 HPA, 4 mild and 6 classical PKU) on dietary treatment were evaluated (anthropometry, body composition, blood pressure measurements, biochemical markers including vitamin, mineral, lipids, carbohydrates and protein status/metabolism, and nutritional intake assessment) at two different annual reviews. The mean time taking AA was 13±5 months and GMP 13±7 months. Blood phenylalanine (PHE) and tyrosine (TYR) were analysed before and after GMP introduction. Both GMP and AA protein substitutes provided similar protein equivalent intake (0.85 vs 0.75 g/kg/day, P=0.182). In the GMP group, it contributed 57% (27-100%) of the protein substitute intake (with AA delivering the rest of protein substitute intake), providing an additional 34±12 mg/day PHE. Nutritional intake, anthropometry and body composition measurements were similar in both the groups. Median blood PHE did not change (P=0.594), although values within target range improved (36 vs 46%), but this was not statistically significant. Mean blood TYR increased (52.0±19.2 vs 63.2±25.6 μmol/l, P=0.033), and all biochemical markers remained stable, except for a lower A1C haemoglobin (P=0.011). Partial GMP contribution to total protein substitute intake did not affect nutritional status in patients with PKU. Blood PHE control was not adversely affected. The increased blood TYR after GMP introduction necessitates further study.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Nutritional status in patients with phenylketonuria using glycomacropeptide as their major protein source

Pinto, A ; Almeida, M F ; Ramos, P C ; Rocha, S ; Guimas, A ; Ribeiro, R ; Martins, E ; Bandeira, A ; MacDonald, A ; Rocha, J C

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.